Avapritinib
| CAS No. | 1703793-34-3 | Cat. No. | BCP20175 |
| Name | Avapritinib | ||
| Synonyms | BLU-285; BLU 285; BLU285; | ||
| Formula | C26H27FN10 | M. Wt | 498.57 |
| Description | BLU-285, also known as Avapritinib, is a potent and selective inhibitor of PDGFRα D842V and KIT Exon 17 mutants and is being developed as a highly targeted therapy for SM, a disorder of the mast cells in which a KIT Exon 17 mutation is the primary driver of disease. BLU-285 is currently being developed by Blueprint. | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase | ||
| Targets | c Kit | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.